In managing ascites in a patient with liver cirrhosis, what is the primary purpose of administering spironolactone?

Choice A reason: Spironolactone is a potassium-sparing diuretic that acts as an aldosterone antagonist. In cirrhosis, secondary hyperaldosteronism causes significant sodium and water retention. By blocking aldosterone, spironolactone increases sodium excretion in the distal tubules, which helps reduce the accumulation of ascitic fluid while minimizing the loss of potassium. Choice B reason: Enhancing water reabsorption would worsen ascites and edema. The goal of diuretic therapy in liver cirrhosis is to inhibit the reabsorption of water and sodium to decrease the total volume of fluid in the peritoneal space and the interstitial tissues, thereby relieving pressure and discomfort. Choice C reason: While spironolactone does reduce potassium secretion as a side effect of its mechanism, this is not the primary clinical "purpose" for its use in managing ascites. Its therapeutic goal is fluid reduction; the potassium-sparing property is simply a benefit or a factor to monitor to avoid hyperkalemia during treatment. Choice D reason: Spironolactone does not have a direct physiological effect on promoting hepatic blood flow. Its primary action is renal. While reducing systemic fluid overload may indirectly ease the burden on the cardiovascular system, it does not specifically target or improve the portal hypertension or intrahepatic resistance characteristic of cirrhosis.